文献速递泌尿生殖与妇科肿瘤放疗

多参数磁共振成像预测接受前列腺癌立体定向体部放疗患者的PSA反应

Multiparametric MRI as a Predictor of PSA Response in Patients Undergoing Stereotactic Body Radiation Therapy for Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2023-11-20

本研究回顾性分析2015年11月至2021年3月在本院接受直线加速器立体定向体部放疗(3625 cGy分5次)的前列腺癌患者123例,评估治疗前多参数磁共振成像(mpMRI)特征与PSA最低值及达最低值时间的关联。结果显示病灶最大径、病灶数目和最高PI-RADS评分均预测PSA最低值及达最低值时间(P<.0001),未接受雄激素剥夺治疗(ADT)者关联持续(P<.001),接受ADT者仅与达最低值时间相关(P<.01)。

要点

  • 治疗前mpMRI病灶最大径、病灶数目和最高PI-RADS评分均预测PSA最低值及达最低值时间(P<.0001)。
  • 未接受ADT患者中上述关联持续存在(P<.001)。
  • 接受ADT患者中上述变量仅与达最低值时间相关(P<.01),与PSA最低值无关(P>0.30)。

核心结论

  • 多参数磁共振成像(mpMRI)对接受立体定向体部放疗(SBRT)伴或不伴ADT的前列腺癌患者的PSA结局具有显著预测能力。
  • 由于PSA最低值已被证明与生化失败相关,该信息可能帮助放射肿瘤科医生更好地向患者说明SBRT后的结局,并可为未来关于哪些患者可能从治疗强化(例如ADT和/或对优势前列腺内病灶加量)中获益的研究提供信息。

研究设计与样本

  • 回顾性识别2015年11月至2021年3月在本院接受直线加速器SBRT至3625 cGy分5次、伴或不伴ADT的所有患者,所有患者治疗前均接受MRI检查。
  • 共纳入123例男性患者。
  • 采用两样本t检验比较术前mpMRI特征与临床结局。

主要发现

  • 治疗前MRI变量包括前列腺内最大病灶的中位直径、中位前列腺病灶数目和中位最高PI-RADS评分,均预测PSA最低值和达PSA最低值时间(P<.0001)。
  • 按ADT治疗分层后,未接受ADT的患者中该关联持续存在(P<.001)。
  • 在接受ADT的患者中,治疗前MRI变量均与达PSA最低值时间显著相关(P<.01),但与PSA最低值无关(P>0.30)。
  • 中位随访时间15.9个月(IQR:8.5-23.3),仅3例患者(2.4%)根据Phoenix标准出现生化复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To maximize the therapeutic ratio, it is important to identify adverse prognostic features in men with prostate cancer, especially among those with intermediate risk disease, which represents a heterogeneous group. These men may benefit from treatment intensification. Prior studies have shown pretreatment mpMRI may predict biochemical failure in patients with intermediate and/or high-risk prostate cancer undergoing conventionally fractionated external beam radiation therapy and/or brachytherapy. This study aims to evaluate pretreatment mpMRI findings as a marker for outcome in patients undergoing stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: We identified all patients treated at our institution with linear accelerator based SBRT to 3625 cGy in 5 fractions, with or without androgen deprivation therapy (ADT) from November 2015 to March 2021. All patients underwent pretreatment Magnetic Resonance Imaging (MRI). Posttreatment Prostate Specific Imaging (PSA) measurements were typically obtained 4 months after SBRT, followed by every 3 to 6 months thereafter. A 2 sample t test was used to compare preoperative mpMRI features with clinical outcomes. RESULTS: One hundred twenty-three men were included in the study. Pretreatment MRI variables including median diameter of the largest intraprostatic lesion, median number of prostate lesions, and median maximal PI-RADS score, were each predictive of PSA nadir and time to PSA nadir (P < .0001). When separated by ADT treatment, this association remained for patients who were not treated with ADT (P < .001). In patients who received ADT, the pretreatment MRI variables were each significantly associated with time to PSA nadir (P < .01) but not with PSA nadir (P > 0.30). With a median follow-up time of 15.9 months (IQR: 8.5-23.3), only 3 patients (2.4%) experienced biochemical recurrence as defined by the Phoenix criteria. CONCLUSIONS: Our experience shows the significant ability of mpMRI for predicting PSA outcome in prostate cancer patients treated with SBRT with or without ADT. Since PSA nadir has been shown to correlate with biochemical failure, this information may help radiation oncologists better counsel their patients regarding outcome after SBRT and can help inform future studies regarding who may benefit from treatment intensification with, for example, ADT and/or boosts to dominant intraprostatic lesions.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Rayn K, Deutsch I, Jeffers B, et al. Multiparametric MRI as a Predictor of PSA Response in Patients Undergoing Stereotactic Body Radiation Therapy for Prostate Cancer. Adv Radiat Oncol. 2023. PMID: 38304110. doi:10.1016/j.adro.2023.101408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。